| Electroporation gene therapy preclinical and clinical trials for melanoma. | |
| | |
MedLine Citation:
|
PMID: 20557286 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In vivo electroporation (EP) is a versatile delivery method for gene transfer which can be applied to any accessible tissue. Delivery of plasmid DNA encoding therapeutic genes or cDNAs with in vivo EP has been tested extensively in preclinical melanoma models. Direct delivery to the tumor has been shown to generate a direct antitumor effect. Delivery to alternative sites may generate additional therapeutic options, for example the production of cancer vaccines, the reduction of tumor angiogenesis, or the induction of tumor cell apoptosis. Several of the preclinical therapies tested have a demonstrated therapeutic effect against melanomas. Two immunotherapies have advanced to melanoma clinical trials. Delivery of a plasmid DNA encoding interleukin-12 (IL-12) or interleukin-2 (IL-2) using electroporation was demonstrated to be a safe with no grade 3 or 4 toxicities reported. Delivery of IL-12 with electroporation resulted in significant necrosis of melanoma cells in the majority of treated tumors and significant lymphocytic infiltrate in biopsies from patients in several cohorts. In addition, clinical evidence of responses in untreated lesions suggested the induction of a systemic response following therapy. This review discusses preclinically tested electroporation gene therapies for melanoma with clinical potential and the conversion of these therapies to clinical trials. |
| | |
Authors:
|
Loree C Heller; Richard Heller |
Related Documents
:
|
18836566 - Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell gro... 20109236 - Autologous tumor-derived heat-shock protein peptide complex-96 (hsppc-96) in patients w... 12581616 - Nitroxyl radicals and malignant pigment melanoma. 20655286 - Progress in understanding melanoma propagation. 17804736 - Real-time imaging of tumor-cell shedding and trafficking in lymphatic channels. 18563556 - Expression profiling of familial breast cancers demonstrates higher expression of fgfr2... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current gene therapy Volume: 10 ISSN: 1875-5631 ISO Abbreviation: Curr Gene Ther Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-19 Completed Date: 2010-12-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101125446 Medline TA: Curr Gene Ther Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 312-7 Citation Subset: IM |
Affiliation:
|
Frank Reidy Research Center for Bioelectrics, Old Dominion University, 4211 Monarch Way, Suite 300, Norfolk, VA 23508, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Clinical Trials as Topic Electrochemotherapy / methods* Female Gene Therapy / adverse effects, methods* Gene Transfer Techniques / adverse effects Humans Interleukin-12 / adverse effects, genetics, therapeutic use Interleukin-2 / adverse effects, genetics, therapeutic use Melanoma / therapy* Mice Neovascularization, Pathologic / therapy Plasmids / adverse effects, therapeutic use Skin Neoplasms / therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Interleukin-2; 187348-17-0/Interleukin-12 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nucleic acids electrotransfer in vivo: mechanisms and practical aspects.
Next Document: Observations of the mechanisms of electromediated DNA uptake--from vesicles to tissues.